Kantar Health in the News

Filter by

Therapeutic Area / Research

Year Starting

Year Ending

Search News:
Showing 1 to 10 of 272

The Future of Brand Management

pharmaphorum, Aug 9, 2017

Read more | Share

Market Segmentation in Healthcare Starts within an Organization

GRBN, Jun 19, 2017

Read more | Share

Nokia, Kantar collaborate for diabetes database project

Pharmaphorum, May 23, 2017

Read more | Share

Behind the Brand — Lessons Learned

PharmaVoice, May 1, 2017

Read more | Share

Lower stress and improve research insights with improvisational comedy

Quirks Media, Apr 25, 2017

Read more | Share

Healthcare industry, or consumer health industry?

Healthcare IT News, Feb 13, 2017

Our industry is diligently working to understand and address the evolution of the healthcare consumer. However, it is still a reactive response. Instead, we need to proactively and strategically prepare for and manage the evolution.

Read more | Share

Trump's Plan for Lowering Big Pharma Drug Prices Comes at a High Cost

Newsweek, Feb 3, 2017

On the last day in January, President Donald Trump met with chief executives from some of the wealthiest pharmaceutical companies in the United States to discuss the future of their industry. The Oval Office meeting, which was closed to the press after opening remarks, included an issue vital to most people not inside the room: the high price of pharmaceuticals.

Read more | Share

Sales of Keytruda miss analysts' mark

MM&M, Feb 2, 2017

Sales of Merck's immunotherapy Keytruda slightly missed analysts' mark for the last three months of 2016, with U.S. sales coming in at $271 million, while consensus estimates were $296 million. Merck initially reported Keytruda sales of $311 million, but that figure included $40 million in deferred revenue.

Read more | Share

Opdivo Making Strides in Advanced Hepatocellular Carcinoma

Oncology Business Review, Jan 23, 2017

It is an exciting time for patients and their doctors fighting advanced hepatocellular carcinoma (HCC).

Read more | Share

Opdivo Shows Appetite for Gastric Cancer

Oncology Business Review, Jan 20, 2017

Before Cyramza® (ramucirumab, Eli Lilly and Co) was approved by the U.S. Food and Drug Administration (FDA) in 2014, no targeted therapy regimens were approved for use in relapsed/refractory gastric cancer.

Read more | Share
Page  < 12345678910 >